NFL Biosciences H1 2026 Net Loss Narrows 15% to EUR 1.53 Million

PUBT · 2d ago
NFL Biosciences H1 2026 Net Loss Narrows 15% to EUR 1.53 Million
  • NFL Biosciences’ first-half 2026 net loss narrowed 15% year-on-year to EUR 1.53 million, with no revenue.
  • Cash fell 15% year-on-year to EUR 2.48 million at June 30, with funding expected to last through first-half 2027.
  • The NFL-102 phase 2 TONIC trial targets initial enrollment in November 2026, with part A results expected in April 2027.
  • Partner searches continue to fund TONIC’s part B and NFL-101’s phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NFL Biosciences SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.